Your browser doesn't support javascript.
loading
Higher than standard dosing regimen are needed to achieve optimal antibiotic exposure in critically ill patients with augmented renal clearance receiving piperacillin-tazobactam administered by continuous infusion.
Carrié, Cédric; Legeron, Rachel; Petit, Laurent; Ollivier, Julien; Cottenceau, Vincent; d'Houdain, Nicolas; Boyer, Philippe; Lafitte, Mélanie; Xuereb, Fabien; Sztark, François; Breilh, Dominique; Biais, Matthieu.
Afiliación
  • Carrié C; Anesthesiology and Critical Care Department, CHU Bordeaux, 33000 Bordeaux, France. Electronic address: cedric.carrie@chu-bordeaux.fr.
  • Legeron R; Pharmacy and Clinical Pharmacy Department, CHU Bordeaux, 33000 Bordeaux, France; Pharmacokinetics and PK/PD Group INSERM 1034, Univ. Bordeaux, 33000 Bordeaux, France. Electronic address: rachel.legeron@chu-bordeaux.fr.
  • Petit L; Anesthesiology and Critical Care Department, CHU Bordeaux, 33000 Bordeaux, France. Electronic address: laurent.petit@chu-bordeaux.fr.
  • Ollivier J; Pharmacy and Clinical Pharmacy Department, CHU Bordeaux, 33000 Bordeaux, France. Electronic address: julien.ollivier@chu-bordeaux.fr.
  • Cottenceau V; Anesthesiology and Critical Care Department, CHU Bordeaux, 33000 Bordeaux, France. Electronic address: vincent.cottenceau@chu-bordeaux.fr.
  • d'Houdain N; Pharmacy and Clinical Pharmacy Department, CHU Bordeaux, 33000 Bordeaux, France. Electronic address: nicolas.d'houdain@chu-bordeaux.fr.
  • Boyer P; Anesthesiology and Critical Care Department, CHU Bordeaux, 33000 Bordeaux, France.
  • Lafitte M; Anesthesiology and Critical Care Department, CHU Bordeaux, 33000 Bordeaux, France. Electronic address: melanie.lafitte@chu-bordeaux.fr.
  • Xuereb F; Pharmacy and Clinical Pharmacy Department, CHU Bordeaux, 33000 Bordeaux, France; Pharmacokinetics and PK/PD Group INSERM 1034, Univ. Bordeaux, 33000 Bordeaux, France. Electronic address: fabien.xuereb@chu-bordeaux.fr.
  • Sztark F; Anesthesiology and Critical Care Department, CHU Bordeaux, 33000 Bordeaux, France; Univ. Bordeaux Segalen, 33000 Bordeaux, France. Electronic address: francois.sztark@chu-bordeaux.fr.
  • Breilh D; Pharmacy and Clinical Pharmacy Department, CHU Bordeaux, 33000 Bordeaux, France; Pharmacokinetics and PK/PD Group INSERM 1034, Univ. Bordeaux, 33000 Bordeaux, France. Electronic address: dominique.breilh@chu-bordeaux.fr.
  • Biais M; Anesthesiology and Critical Care Department, CHU Bordeaux, 33000 Bordeaux, France; Univ. Bordeaux Segalen, 33000 Bordeaux, France. Electronic address: matthieu.biais@chu-bordeaux.fr.
J Crit Care ; 48: 66-71, 2018 12.
Article en En | MEDLINE | ID: mdl-30172963
ABSTRACT

PURPOSE:

To determine whether augmented renal clearance (ARC) impacts negatively on piperacillin-tazobactam unbound concentrations in critically ill patients receiving 16 g/2 g/day administered continuously. MATERIAL AND

METHODS:

Fifty nine critically ill patients without renal impairment underwent 24-h creatinine clearance (CrCL) measurement and therapeutic drug monitoring during the first three days of antimicrobial therapy by piperacillin-tazobactam. The main outcome was the rate of piperacillin underexposure, defined by at least one of three samples under 16 mg/L. Monte Carlo simulation was performed to predict the distribution of piperacillin concentrations for various CrCL and minimal inhibitory concentration (MIC) values.

RESULTS:

The rate of piperacillin underexposure was 19%, significantly higher in ARC patients (0 vs. 31%, p = .003). A threshold of CrCL ≥ 170 mL/min had a sensitivity and specificity of 1 (95%CI 0.79-1) and 0.69 (95%CI 0.61-0.76) to predict piperacillin underexposure. In ARC patients, a 20 g/2.5 g/24 h PTZ dosing regimen was associated with the highest probability to reach the 16 mg/L empirical target, without risk of excessive dosing.

CONCLUSIONS:

When targeting a theoretical MIC at the upper limit of the susceptibility range, the desirable target (100%fT>16) may not be achieved in patients with CrCL ≥ 170 mL/min receiving PTZ 16 g/2 g/day administered continuously.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Sepsis / Combinación Piperacilina y Tazobactam / Antibacterianos Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Crit Care Asunto de la revista: TERAPIA INTENSIVA Año: 2018 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Sepsis / Combinación Piperacilina y Tazobactam / Antibacterianos Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Crit Care Asunto de la revista: TERAPIA INTENSIVA Año: 2018 Tipo del documento: Article